0.047 and 0.117, respectively. Overall, among the ALL patients only 20.6% carried at least one of the polymorphisms, while this rate was 34.6% within the control population. This difference is statistically significant (w 2 ¼ 5.2266, Po0.025). The results are summarized in Table 1. No significant differences were observed concerning ALL immunophenotype, sex, age at diagnosis, survival rate, or risk of relapse.These results implicate that the two polymorphisms A3V and T9I do not increase the risk of ALL in children, but rather suggest that they could convey a protective effect. Roddam et al.

The present study was conducted to evaluate the efficacy and safety of a combination regimen of docetaxel plus oxaliplatin in patients with advanced gastric cancer. Patients with previously untreated metastatic or recurrent, measurable gastric cancer received intravenous docetaxel 65 mg m À2 plus oxaliplatin 120 mg m À2 on day 1 based on a 3-week cycle. Forty-two patients were enrolled in the current study, among whom 39 were assessable for efficacy and all assessable for toxicity. One complete response and 18 partial responses were confirmed, giving an overall response rate of 45.2% (95% confidence interval (CI); 31.7 -59.7%). At a median followup of 7.7 months, the median time to progression and median overall survival was 5.7 (95% CI; 4.3 -7.2) months and 9.9 (95% CI; 7.8 -12.0) months, respectively. Grade 3/4 neutropenia occurred in 11 patients (26.1%) and febrile neutropenia was observed in four patients (9.5%). The common non-haematologic toxicity was fatigue (grade 1/2, 61.9%) and nausea (grade 1/2, 47.7%). The combination of docetaxel and oxaliplatin was found to be well tolerated and effective in patients with advanced gastric cancer.

A facile hydrothermal method was adopted to in situ grow ZnO nanowire pyramidal bundle arrays on zinc substrates at low growth temperature without the assistance of catalysts and templates. The bundle arrays were shown to form by sticking of nanowires at their tips. Field electron emission characterization of nanowires bundle arrays revealed a very low turn-on electric field of about 2.3 V/microm and a threshold electric field (corresponding to the field electron emission current density of 10 mA/cm2) of 6.8 V/microm, which are comparable to those observed in carbon nanotube arrays. The bundle arrays also show pronounced long-term field electron emission stability at a high current density. In addition, the formation mechanism of the pyramidal bundled arrays and the origin of the peculiar field electron emission properties were discussed.

There is no apparent early advantage in terms of response or survival conferred by adding the study INF regimen to CHOP therapy for patients with IG/HG-NHL.